After administration of mobilizing regimens ( primarily high-dose etoposide , high-dose cyclophosphamide , intermediate-dose Ara-C or ESHAP ) , patients were randomized to a standard daily @ g/kg dose of biosimilar G-CSF ( n = @ ) or originator G-CSF ( n = @ ) .